These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30631963)

  • 1. Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials.
    Jia X; Kohli P; Virani SS
    Curr Atheroscler Rep; 2019 Jan; 21(1):1. PubMed ID: 30631963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
    Rupp H
    Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
    Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
    Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.
    Quispe R; Alfaddagh A; Kazzi B; Zghyer F; Marvel FA; Blumenthal RS; Sharma G; Martin SS
    Curr Atheroscler Rep; 2022 Jul; 24(7):571-581. PubMed ID: 35499805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
    Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
    Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
    Kar S
    Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists.
    Patel D; Busch R
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):524-532. PubMed ID: 34191622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
    Harris WS; Dayspring TD; Moran TJ
    Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease.
    Sweeney TE; Gaine SP; Michos ED
    Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):87-93. PubMed ID: 36562280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
    Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Kwak SM; Myung SK; Lee YJ; Seo HG;
    Arch Intern Med; 2012 May; 172(9):686-94. PubMed ID: 22493407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention.
    Kapoor K; Alfaddagh A; Stone NJ; Blumenthal RS
    J Clin Lipidol; 2021; 15(4):545-555. PubMed ID: 34294561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New evidence for the cardiovascular benefits of long chain omega-3 fatty acids.
    Hansen SN; Harris WS
    Curr Atheroscler Rep; 2007 Dec; 9(6):434-40. PubMed ID: 18377782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease: From fish to pharmaceuticals.
    Bosomworth NJ
    Can Fam Physician; 2023 Jul; 69(7):459-468. PubMed ID: 37452000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History and future of omega-3 fatty acids in cardiovascular disease.
    Sperling LS; Nelson JR
    Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
    Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495
    [No Abstract]   [Full Text] [Related]  

  • 20. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
    Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
    Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.